Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates dextran sulfate sodium-induced colitis in mice

International Immunopharmacology

Volumn 12, Issue 1, 2012, Pages 169-174

  Zhao, Zhi Jing ^a   Xiang, Jun Ying ^b   Liu, Liu ^a   Huang, Xiao Li ^a   Gan, Hua Tian ^a  

^a SICHUAN UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Dextran sulfate sodium induced colitis; Nuclear factor (NF) B; Parthenolide; Ulcerative colitis

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MYELOPEROXIDASE; PARTHENOLIDE; PHOSPHOPROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; DRUG ADMINISTRATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL MOUSE; HISTOPATHOLOGY; INTRACOLONIC ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; I-KAPPA B PROTEINS; MALE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PEROXIDASE; SESQUITERPENES;

EID: 84856089700     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.11.007     Document Type: Article

References (39)

1. D.K. Podolsky Inflammatory bowel disease N Engl J Med 347 2002 417 429 (Pubitemid 34851835)
2. B.E. Sands Therapy of inflammatory bowel disease Gastroenterology 118 2000 S68 S82
3. J.A. Katz Advances in the medical therapy of inflammatory bowel disease Curr Opin Gastroenterol 18 2002 435 440 (Pubitemid 34665102)
4. J.G. Reddy, and E.V. Loftus Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases Gastroenterol Clin North Am 35 2006 837 855 (Pubitemid 44802970)
5. K.A. Papadakis, and S.R. Targan Role of cytokines in the pathogenesis of inflammatory bowel disease Annu Rev Med 51 2000 289 298 (Pubitemid 30216038)
6. G. Rogler, and T. Andus Cytokines in inflammatory bowel disease World J Surg 22 1998 382 389 (Pubitemid 28113526)
7. C. Stevens, G. Walz, C. Singaram, M.L. Lipman, B. Zanker, and A. Muggia Tumor necrosis factor-a, interleukin-1, and interleukin-6 expression in inflammatory bowel disease Dig Dis Sci 37 1992 818 826
8. T.S. Blackwell, and J.W. Christman The role of nuclear factor-κB in cytokine gene regulation Am J Respir Cell Mol Biol 17 1997 3 9 (Pubitemid 127500814)
9. P. Baeuerle, and T. Henkel Function and activation of NF-κB in the immune system Annu Rev Immunol 12 1994 141 153
10. A.S. Baldwin The NF-kappa B and I kappa B proteins: new discoveries and insights Annu Rev Immunol 14 1996 649 683
11. G. Rogler, K. Brand, D. Vogl, S. Page, R. Hofmeister, and T. Andus Nuclear factor-κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa Gastroenterology 115 1998 537 569
12. S. Schreiber, S. Nikolaus, and J. Hampe Activation of nuclear factor-κB in inflammatory bowel disease Gut 42 1998 477 484 (Pubitemid 28186562)
13. M.F. Neurath, S. Pettersson, Z.U.M. Meyer, K.H. Büschenfelde, and W. Strober Local administration of antisense phosphorothioate oligonucleotide to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice Nat Med 2 1996 998 1004 (Pubitemid 26306838)
14. S. Fichtner-Feigl, I.J. Fuss, J.C. Preiss, W. Strober, and A. Kitani Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides J Clin Invest 115 2005 3057 3071 (Pubitemid 41567571)
15. J.Y. Xiang, L.G. Wu, X.L. Huang, M. Zhang, L. Pen, O. Ouyan, and H.T. Gan Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappa b decoy oligonucleotides Am J Surg 197 2009 797 804
16. C.J. Sweeney, S. Mehrotra, M.R. Sadaria, S. Kumar, N.H. Shortle, and Y. Roman The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer Mol Cancer Ther 4 2005 1004 1012 (Pubitemid 40909083)
17. A. Saadane, S. Masters, J. DiDonato, J. Li, and M. Berger Parthenolide inhibits IκB kinase, NF-κB activation, and inflammatory response in cystic fibrosis cells and mice Am J Respir Cell Mol Biol 36 2007 728 736 (Pubitemid 46871428)
18. N. Miyata, Y. Gon, S. Nunomura, D. Endo, K. Yamashita, and K. Matsumoto Inhibitory effects of parthenolide on antigen-induced microtubule formation and degranulation in mast cells Int Immunopharmacol 8 2008 874 880
19. S.P. Hehner, M. Heinrich, P.M. Bork, M. Vogt, F. Ratter, and V. Lehmann Sesquiterpene lactones specifically inhibit activation of NF-κB by preventing the degradation of IκB-α and IκB-β J Biol Chem 273 1998 1288 1297 (Pubitemid 28133643)
20. S.P. Hehner, T.G. Hofmann, W. Droge, and M.L. Schmitz The anti-inflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex J Immunol 163 1999 5617 5623
21. B.H.B. Kwok, B. Koh, M.I. Ndubuisi, M. Elofsson, and C.M. Crews The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IUB kinase Chem Biol 8 2001 759 766 (Pubitemid 32752455)
22. B.Y. Kang, S.W. Chung, and T.S. Kim Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-κB Immunol Lett 77 2001 159 163 (Pubitemid 32532070)
23. O. Lopez-Franco, P. Hernandez-Vargas, G. Ortiz-Munoz, Y. Suzuki, G. Sanjuan, L. Ortega, and J. Blanco Parthenolide modulates the NF-κB-mediated inflammatory responses in experimental atherosclerosis Arterioscler Thromb Vasc Biol 26 2006 1864 1870 (Pubitemid 44305342)
24. S.N.S. Murthy, H.S. Cooper, H. Shim, R.S. Shah, S.A. Ibrahim, and D.J. Sedergran Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin Dig Dis Sci 38 1993 1722 1734 (Pubitemid 23271431)
25. T. ten Hove, B. van den Blink, I. Pronk, P. Drillenburg, M.P. Peppelenbosch, and S.J.H. van Deventer Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis Gut 50 2002 507 512 (Pubitemid 34638870)
26. I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice Gastroenterology 98 1990 694 702 (Pubitemid 20069706)
27. M.F. Neurath, I. Fuss, G. Schurmann, S. Pettersson, K. Arnold, and H. Müller-Lobeck Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease Ann NY Acad Sci 859 1998 149 159 (Pubitemid 29021014)
28. B. Zingarelli, P.W. Hake, A. Denenberg, and H.R. Wong Sesquiterpene lactone parthenolide, an inhibitor of I[kappa]B kinase complex and nuclear factor-[kappa]B, exerts beneficial effects in myocardial reperfusion injury Shock 17 2002 127 134
29. W.B. Song, Y.Y. Wang, F.S. Meng, Q.H. Zhang, J.Y. Zeng, and L.P. Xiao Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation PLoS One 5 2010 e12969
30. K. Tanaka, J. Hasegawa, K. Asamitsu, and T. Okamoto Prevention of the ultraviolet B-mediated skin photoaging by a nuclear factor-κB inhibitor, parthenolide J Pharmacol Exp Ther 315 2005 624 630 (Pubitemid 41500727)
31. M. Sheehan, H.R. Wong, P.W. Hake, V. Malhotra, M. O'Connor, and B. Zingarelli Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents Mol Pharmacol 61 2002 953 963 (Pubitemid 34441759)
32. A. Mantovani, M. Muzio, C. Garlanda, S. Sozzani, and P. Allavena Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines Novartis Found Symp 234 2001 120 131
33. N. Auphan, J.A. DiDonato, C. Rosette, A. Helmberg, and M. Karin Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis Science 270 1995 286 290
34. C.K. Weber, S. Liptay, T. Wirth, G. Adler, and R.M. Schmid Suppression of NF-kappa B activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta Gastroenterology 119 2000 1209 1218
35. K. Nakamura, K. Honda, T. Mizutani, H. Akiho, and N. Harada Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules World J Gastroenterol 12 2006 4628 4635 (Pubitemid 44269718)
36. M. Sheehan, H.R. Wong, P.W. Hake, and B. Zingarelli Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis Crit Care Med 31 2003 2263 2270 (Pubitemid 37100827)
37. H. Nakshatri, S.E. Rice, and P. Bhat-Nakshatri Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase Oncogene 23 2004 7330 7344 (Pubitemid 39382136)
38. E.A. Curry 3rd, D.J. Murry, C. Yoder, K. Fife, V. Armstrong, and H. Nakshatri Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer Invest New Drugs 223 2004 299 305 (Pubitemid 39012569)
39. J.J. Murphy, S. Heptinstall, and J.R. Mitchell Randomized double-blind placebo-controlled trial of feverfew in migraine prevention Lancet 2 1988 189 192